Abstract
Children with problematic asthma represent about 0.5% of the population but consume a disproportionate amount of healthcare staff time and resources. The most important step in managing children with problematic asthma is differentiating those with genuine severe, therapy resistant disease from those who have difficult to treat asthma for a variety of other remediable factors. The most common causes of poor symptom control are poor adherence to therapy, ongoing exposure to sensitized allergens or co-morbid psychosocial problems. In up to half of the children with problematic asthma, addressing these simple factors can avoid further escalation of treatment or more invasive investigation. All asthmatic children with poor control despite treatment with ≥ 800μg of inhaled budesonide (or equivalent) should be referred to a paediatric respiratory specialist for evaluation. Management of children with problematic asthma, and particularly those with genuine severe therapy resistant disease, requires a stepwise multidisciplinary approach.
Keywords: Asthma, problematic, severe, difficult, adherence, steroid-sparing
Current Pediatric Reviews
Title: Severe Asthma: Why do Some Children Not Respond to Treatment?
Volume: 6 Issue: 2
Author(s): Ruth O'Reilly and Sejal Saglani
Affiliation:
Keywords: Asthma, problematic, severe, difficult, adherence, steroid-sparing
Abstract: Children with problematic asthma represent about 0.5% of the population but consume a disproportionate amount of healthcare staff time and resources. The most important step in managing children with problematic asthma is differentiating those with genuine severe, therapy resistant disease from those who have difficult to treat asthma for a variety of other remediable factors. The most common causes of poor symptom control are poor adherence to therapy, ongoing exposure to sensitized allergens or co-morbid psychosocial problems. In up to half of the children with problematic asthma, addressing these simple factors can avoid further escalation of treatment or more invasive investigation. All asthmatic children with poor control despite treatment with ≥ 800μg of inhaled budesonide (or equivalent) should be referred to a paediatric respiratory specialist for evaluation. Management of children with problematic asthma, and particularly those with genuine severe therapy resistant disease, requires a stepwise multidisciplinary approach.
Export Options
About this article
Cite this article as:
O'Reilly Ruth and Saglani Sejal, Severe Asthma: Why do Some Children Not Respond to Treatment?, Current Pediatric Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339610791561150
DOI https://dx.doi.org/10.2174/157339610791561150 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs of Abuse-Induced Hyperthermia, Blood-Brain Barrier Dysfunction and Neurotoxicity: Neuroprotective Effects of a New Antioxidant Compound H-290/51
Current Pharmaceutical Design The Reactivity of Free Radicals in Biomass Char Studied by EPR Spectroscopy
Mini-Reviews in Organic Chemistry Estrogen Receptor Ligands for Targeting Breast Tumours: A Brief Outlook on Radioiodination Strategies
Current Radiopharmaceuticals Synthesis, Anti-inflammatory Activities and Mechanisms of 3,5- dihydroxycinnamic Acid Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Mechanisms of Anti-retroviral Drug Resistance: Implications for Novel Drug Discovery and Development
Infectious Disorders - Drug Targets Targeting DNA G-Quadruplex Structures with Peptide Nucleic Acids
Current Pharmaceutical Design Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging Progress in Understanding Basal Ganglia Dysfunction as a Common Target for Methamphetamine Abuse and HIV-1 Neurodegeneration
Current HIV Research Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Isoform Selective Phosphoinositide 3-Kinase γ and δ Inhibitors and Their Therapeutic Potential
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds
Medicinal Chemistry Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Abscisic Acid: A Versatile Phytohormone in Plant Signaling and Beyond
Current Protein & Peptide Science Diabetes Mellitus as a Risk Factor for Cancer: Stress or Viral Etiology?
Infectious Disorders - Drug Targets Current Status and Recent Developments in Anthracenone Antipsoriatics
Current Pharmaceutical Design Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Intervertebral Disc and Nucleus Replacement Devices and Instrumentations
Recent Patents on Biomedical Engineering (Discontinued) TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery